Compare companies
Valneva SE | Gilead Sciences | Amgen | ||||
---|---|---|---|---|---|---|
Capitalization | ||||||
Price | 6.79 | 113.99 | 312.5 | |||
Price priv. | ||||||
Number of shares, million | 138.62 | 1258 | 538 | |||
Capitalization, billion | 0.8989 | 94.55 | 140.05 | |||
EBITDA, billion | -0.0865 | 7.61 | 7.9 | |||
EV, billion | 1.34 | 119.11 | 206.55 | |||
Profit and loss report | ||||||
Net profit, billion | -0.1014 | 5.67 | 6.72 | |||
Revenue, billion | 0.1537 | 27.12 | 28.19 | |||
EPS | -0.7317 | 4.5 | 12.49 | |||
Balance | ||||||
Assets, billion | 0.4694 | 62.13 | 97.15 | |||
Debt, billion | 0.1797 | 24.99 | 64.61 | |||
Balance cost, billion | 0.1282 | 22.75 | 6.23 | |||
Cash, billion | 0.1261 | 6.09 | 10.94 | |||
Coefficients | ||||||
Dividend yield, % | 0 | 3.65 | 2.91 | |||
Dividend | 0 | 3.87 | 9.13 | |||
Dividend yield priv., % | 0 | 0 | 0 | |||
Dividend priv. | 0 | 0 | 0 | |||
Dividends/profit, % | 0 | 67.24 | 67.83 | |||
P/S | 8.16 | 3.7 | 5.42 | |||
P/BV | 9.78 | 4.41 | 24.53 | |||
P/E | 6.47 | 17.69 | 22.76 | |||
Ev/Ebitda | -15.45 | 15.66 | 26.16 | |||
Debt/Ebitda | -2.08 | 3.29 | 8.18 | |||
Efficiency | ||||||
ROE | -79.09 | 24.9 | 107.78 | |||
ROA | -21.61 | 9.12 | 6.91 | |||
ROIC | -26.12 | 11.06 | 17 | |||
Ebitda margin | -56.27 | 28.05 | 28.01 | |||
Net margin | -65.99 | 20.89 | 23.83 | |||
Momentum | ||||||
1 week, price changes | -3.96 % | -1.77 % | -1.67 % | |||
1 month, price changes | -18.49 % | +18.57 % | +5.34 % | |||
3 months, price changes | +72.77 % | +23.39 % | +14.03 % | |||
6 months, price changes | +11.86 % | +37.65 % | -6 % | |||
1 year, price changes | -12.09 % | +53.6 % | +15.08 % | |||
3 years, price changes | -80.55 % | +79.23 % | +21.15 % | |||
5 years, price changes | +101.22 % | +40.18 % | ||||
10 years, price changes | +39.37 % | +101.9 % |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription